Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia

NCT01867190 | Completed Phase 2 DMC

• 1 other identifier: IND 15069
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This study will assess the safety and efficacy of intra-arterial infusion and intramuscular injection of an autologous, bone marrow-derived stem cell preparation (ASCT01) in patients with critical limb ischemia who have exhausted all medical and surgical therapeutic options. The safety and tolerability will be evaluated by regular monitoring of the general physical condition, vital signs, and the occurrence of AE and SAE, respectively. Furthermore, the standard biochemical and blood variables (red and white blood cell counts, Hb, Ht, platelets, sodium, potassium, chloride, calcium, phosphor, ASAT, ALAT, bilirubin, total protein, albumin, AP, cholesterol (LDL,HDL), triglycerides, urea and creatinine, immunoglobulins, HBA1c, C-peptide) will be checked before the treatment as well as 30 and 90 days after the treatment.

Conditions

Critical Limb Ischemia

Keywords

CLI

Outcome Measures

Primary Outcomes (1)

• To assess the efficacy and safety of intra-arterial infusion and intramuscular injection of ASCT01 on the combined primary endpoint of major amputation (above the ankle) or persisting critical limb ischemia (no clinical or perfusion improvement).

  The primary outcome variable is "treatment failure" defined as major amputation (above the ankle) of the affected limb within 3 months or an unchanged critical limb ischemia of the affected limb after 3 months defined as less than 15% change in tcPO2 or ABI or absolute ankle pressure.

  primary outcome measured at 3 months

Study Arms (1)

ASCT01

OTHER

ASCT01 (Autologous Stem Cell Transplantation)

Biological: ASCT01 (Autologous Stem Cell Transplantation)

Interventions

ASCT01 (Autologous Stem Cell Transplantation) BIOLOGICAL

Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route

ASCT01

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and Female patients in the age group of 18-80yrs.
• Established CLI (confirmed by Rutherford 4 to 5) with angiographic evidence of significant infra-inguinal arterial occlusive disease
• Ankle Brachial Pressure Index (ABI) ≤ 0.6 or the absolute ankle blood pressure \< 60 mm Hg or TcPO2\<20 mmHg without tissue loss or TcPO2\<40 mmHg if there is tissue loss or alternatively toe Brachial Pressure Index (TBI) less 0.5 or the absolute toe blood pressure less than 50 mm Hg
• No surgical or interventional option for revascularization and no response to best standard care delivered as confirmed by a vascular surgeon and/or physician.
• No immediate life-threatening complication from CLI which would demand immediate amputation.
• Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits.
• On optimal medical therapy
• If diabetic, HgbA1c \<10%

You may not qualify if:

• Acute life threatening complication of limb ischemia with the need for immediate limb amputation to avoid death or clinical deterioration
• Patients with confirmed Rutherford 6 condition with extensive tissue damage
• Patients with documented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 6 months.
• Patients with a history of severe alcohol or drug abuse within 3 months of screening.
• Known bone marrow diseases which preclude transplantation.
• End-stage renal failure on regular dialysis treatment. Creatinine ≥2.0 mg/dl
• Patients already enrolled in another investigational drug trial or completed within 1month.
• Pregnancy.
• Patients tested positive for HIV screen1or2, Hepatitis C antibody Hepatitis B surface-antigen, HepatitisBcore Antibody, Syphilis screen
• Myocardial infarction / CVA / TIA within the past three months prior to enrollment
• Revascularization procedure in target limb within 6 weeks prior to enrollment
• Laboratory values as show below\*
• Currently taking immunosuppressive agents
• If diabetic, diagnosis of proliferative retinopathy
• Patients with infected ulcers or systemic infections \*Laboratory Values: Hemoglobin \<10 g/dL Platelet count \<100,000/microL ALT \>60 U/L AST \>60 U/L Bilirubin \>1.0 mg/dL INR \>1.3 unless on Coumadin and at Investigator discretion APTT \>40 second unless on Lovenox or Heparin and at Investigator's discretion

Sponsors & Collaborators

• Lifecells, LLC.: lead

Study Sites (1)

Kansas City Vascular Foundation (KCV)

North Kansas City, Missouri, 64116, United States

Location

MeSH Terms

Conditions

Chronic Limb-Threatening Ischemia

Condition Hierarchy (Ancestors)

Peripheral Arterial Disease; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Peripheral Vascular Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Ischemia

Study Officials

• Paul T Sudhakar, MS, Pharm

  Lifecells, LLC.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Autologous treatment for CLI open label

Study Record Dates

• First Submitted: May 29, 2013
• First Posted: June 3, 2013
• Study Start: May 1, 2013
• Primary Completion: March 1, 2016
• Study Completion: March 1, 2016
• Last Updated: February 22, 2019

Record last verified: 2019-02

Locations

US (1)